
usd may pm et
summari compani primarili focus discoveri develop commerci
nm price-to-earnings oper ep
sale upward trend free cash flow off-set
compani signific revenu concentr
jakafi high spend
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
expect revenu growth deceler
jakafi sale
revenu growth continu deceler
although signific revenu
concentr jakafi dont anticip
consider competit threat jakafi
domin posit treatment
myelofibrosi mf polycythemia vera pv
least sever year patent
ruxolitinib compound name jakafi
valid decemb
develop ruxolitinib topic
cream atop dermat vitiligo
although manag plan
commerci ruxolitinib cream
 wonder sharehold better
serv collabor commerci
effort given differ ruxolitinib
cream therapi current
market exampl atop dermat
highli contest indic mf
expect commerci
launch three drug believ minor
long-term valu compani pemazyr
capmatinib approv may tafasitamab
 fda approv anticip august
opinion share appropri
reflect valu compani mid-
late-stag pipelin asset exist
substanti relianc drug jakafi expect
littl impact
candid believ ruxolitnib cream
potenti futur sale given
recent announc posit phase trial
data readout ruxolitinib cream atop
dermat anticip new drug
applic submiss fda
phase trial result itacitinib treatment
result diminish confid
itacitinib potenti set
chronic gvhd gvhd prophylaxi
risk opinion target price includ
commerci under-perform jakafi
clinic develop setback poor
target price reflect forward price-to-earnings
multipl ep
estim
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president head
corpor overview incyt corpor biopharmaceut compani primarili focus
discoveri develop commerci proprietari oncolog hematolog therapeut
compani primari product jakafi compound name ruxolitinib compani first
commerci therapeut jakafi first approv food drug administr fda
novemb treatment patient intermedi high risk myelofibrosi mf
approv decemb treatment patient polycythemia vera pv
inadequ respons intoler hydroxyurea myelofibrosi mf polycythemia vera pv
rare blood cancer year end decemb jakafi jakavi compris
inci product revenu accord inci ceo earn call medicar make
 jakafi sale
market jakafi iclusig europ also receiv royalti revenu sale
jakavi name jakafi outsid olumi baricitinib jakavi market novarti
ag olumi market compani
competit ruxolitinib composit matter patent expir decemb mean sale
jakafi jakavi like safe biosimilar competit least could like
extend patent protect ruxolitnib increment patent septemb see
substanti threat sale jakafi jakavi come sever year least
sever aspir competitor tri develop therapeut treat mf pv progress difficult
success competitor far would celgen corp celg receiv fda approv
august fedratinib mf howev expect fedratinib second-lin therapi mf
especi given black box warn encephalopathi concern toxic profil
olumi royalti revenu repres second valuabl asset jakafi receiv tier
royalti global sale howev olumi compet highli competit market
treatment moderate-to-sever rheumatoid arthriti drug black box label stop
fund joint develop olumi focu promis
opportun nonetheless estim olumi could provid million royalti revenu
pipelin larg number clinic candid develop although dont current see
combin clinic candid gener much revenu ruxolitinib next decad
januari clinic candid closest commerci parsaclisib pemigatinib
addit indic ruxolitinib believ ruxolitnib cream atop dermat
vitiligo potenti futur sale
ruxolitinib cream repres diverg inci tradit focu oncolog hematolog
ruxolitinib cream aim treat atop dermat vitiligo fall inflamm
autoimmun iai addit inci iai franchis aim target much broader popul
approxim million potenti patient wherea mf pv rare diseas patient
popul small unlik jakafi ruxolitinib cream face signific competit primarili
atop dermat indic despit differ manag appear lean toward
independ commerci ruxolitinib cream expect phase data readout
ruxolitinib cream atop dermat earli although approv larg expect given strong
phase ii result initi phase trial ruxolitinib cream vitiligo
previous view itacitinib treatment nave acut gvhd promis near-term revenu
opportun howev disappoint phase trial result releas januari
longer assign valu itacitinib inci manag argu clear trial result
readthrough studi itacitinib includ itacitinib chronic
gvhd phase studi gvhd prophylaxi phase studi yet due
complex chronic gvhd recent failur itacitinib acut gvhd hesit assign
valu itacitinib
financi trend total revenu billion billion product
revenu compound annual growth rate compound-annual-growth-rate revenu past five year
reflect rapid sale growth jakafi approv fda revenu growth
deceler expect compound-annual-growth-rate year end ep
adjust ep june gener trailing-twelv month free cash
flow defin cash oper less capit expenditur million billion
cash cash equival market secur addit typic maintain low level
debt suggest us suffici financi capac fund oper make
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
spite global recess
concern posit outlook
histor defens sub-industri
expect see ramp-up new drug sale
continu develop mani new
innov therapi declin
preval patent expir
partli due govern shutdown
earli fda approv new drug
declin
fda approv shatter previou
record sinc novel approv set
new drug typic take least
year reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
expect impact larg
immateri suppli demand side
thing biotech firm although
firm industri could benefit
develop treatment vaccin sever
biotech firm work develop vaccin
treatment includ regeneron gilead
coverag warn investor
effect treatment vaccin often take
year develop difficult
determin whether treatment effect
prior gather signific amount
clinic data also expect substanti
price pressur treatment
commerci given urgent
widespread natur pandem
mean upsid success
treatment like minor
also impact biotech firm
clinic trial delay think
delay mostli immateri
near-term revenu long-term outlook
although deal count biopharmaceut
 lower
past decad total deal valu transact
billion largest amount
sinc accord evaluatepharma
total deal valu driven coupl
mega-d bristol-mey squibb
acquisit celgen
acquisit botox manufactur allergan
decemb biotech industri debt
level remain low rel histor level
rel industri addit
late march sub-industri valuat
sub-industri out-performance
lead us believ like
continu favor
environ biopharma
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen neg impact
profit biotech firm dont
expect drug legisl come back
focu novemb
year-to-d march
biotechnolog index declin vs
declin composit
biotech index increas
rise valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rate begin coverag target price
reflect forward price-to-earnings ratio earn estim ep
estim opinion share
appropri captur valu compani mid- late-stag pipelin asset
exist commerci oper especi substanti relianc drug
jakafi product revenu late-stag pipelin asset
forecast ruxolitnib cream atop dermat vitiligo itacitinib
treatment nave gvhd graft versu host diseas potenti
futur sale expect phase trial data readout itacitinib end
ruxolitinib cream atop dermat posit data
readout like quickli follow regulatori submiss although
compani robust pipelin hesit assign valu early-stag
analyst research note compani news
pm et cfra keep hold opinion share incyt corpor
lift target price reflect forward price-to-earnings
ratio earn earn vs
significantli expect million
up-front payment relat inci collabor morphosi
otherwis result mostli line expect
reiter guidanc indic littl impact
result lower ep ep
share trade late thought
alreadi price april fda approv pemigatinib
call pemazyr bile duct cancer posit data ruxolitinib cream
atop dermat perhap posit sentiment driven
potenti opportun ruxolitinib treat howev manag
comment today doesnt see commerci
opportun magnitud ruxolitinib /kevin huang cfa
pm et cfra maintain hold opinion share incyt corpor
keep target price reflect forward price-to-earnings
ratio earn estim earn vs
surpass expect primarili due lower-than-expect
oper expens keep ep estim start
ep estim product royalti revenu increas yoy
million jakafi sale expand million follow recent
posit result phase trial ruxolitinib cream
patient mild-to-moder atop dermat assum
trial also demonstr posit result later expect submit
new drug applic nda fda also look
forward data parsaclisib efficaci non-hodgkin
lymphoma regulatori decis inci less signific clinic
candid pemigatinib fda decis anticip end may capmatinib
submit nda februari /kevin huang cfa
et cfra maintain hold opinion share incyt corpor
lower price target share reflect
failur itacitinib corticosteroid vs corticosteroid meet
phase trial primari endpoint improv overal respons rate
patient nave acut graft-versus-host diseas gvhd thought
itacitinib could gener million sale howev due
trial unfavor result assign valu itacitinib
special call yesterday manag argu clear
latest trial result read-through studi
itacitinib includ itacitinib chronic gvhd phase studi
gvhd prophylaxi phase studi
howev due complex chronic gvhd recent failur
itacitinib acut gvhd hesit assign valu itacitinib
pm et cfra maintain hold opinion share incyt corpor
keep target price reflect forward price-to-earnings
ratio earn estim earn vs
surpass expect due higher-than-expect sale
lower-than-expect oper expens rais ep estim
total revenu increas yoy million jakafi
sale expand million mid-octob announc posit
result phase trial studi ruxolitinib
steroid-refractori acut graft-versus-host-diseas gvhd indic
recent approv fda result solidifi use ruxolitinib
second line set support continu without modif
phase pivot trial ruxolitinib patient
steroid-refractori chronic gvhd result expect key
near-term catalyst phase result itacitinib acut
gvhd expect end /kevin huang cfa
et cfra initi coverag incyt corpor hold
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
